Management of High Rectal Cancer

Classification and Diagnosis

• Tumors with distal extension to 15 cm or less from the anal margin are classified as rectal cancer, with those between 10-15 cm specifically categorized as high rectal cancer 3
• Diagnosis requires digital rectal examination, endoscopy with biopsy for histopathological confirmation, and complete staging workup, including MRI or endorectal ultrasound and CT scans of chest, abdomen, and pelvis 3, 4

Surgical Management

• For high rectal cancer (>10 cm from anal verge), wide mesorectal excision with removal of at least 5 cm of the rectal mesentery is recommended, rather than total mesorectal excision (TME) 1, 2
• Laparoscopic or robot-assisted approaches may be considered for high rectal cancer, though long-term oncological efficacy still needs further evaluation and should be performed in experienced centers 1, 2

Neoadjuvant and Adjuvant Therapy

• High rectal cancers (10-15 cm) generally do not require routine preoperative chemoradiotherapy unless there are specific high-risk features 1, 2
• For high rectal cancer, adjuvant chemotherapy follows the principles for colon cancer treatment, particularly for stage III disease, and includes oxaliplatin-based regimens (FOLFOX) 1, 6

Special Considerations

• For patients with dMMR/MSI-H tumors, neoadjuvant immunotherapy may be considered, especially for cases with difficulties achieving R0 resection 1, 2
• In cases with confirmed lateral lymph node metastasis on imaging, preoperative neoadjuvant chemoradiotherapy followed by lateral lymph node dissection is recommended 1, 2

Treatment Algorithm

• Initial staging should include complete clinical staging with MRI, endoscopy, and CT scans 3, 4
• Primary treatment for most cases involves upfront surgery with wide mesorectal excision (not TME) 1, 2
• For stage IV disease, a multimodality approach including surgery for resectable metastases may be considered 7

Common Pitfalls and Caveats

• Misclassifying high rectal cancer (10-15 cm) as mid-rectal cancer can lead to overtreatment with unnecessary preoperative chemoradiotherapy 1, 2
• Inadequate lymph node sampling (less than 12 nodes) may result in understaging and suboptimal treatment decisions 6
• Failure to recognize dMMR/MSI-H status may result in missed opportunities for immunotherapy approaches 1, 2